MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

Search

Johnson and Johnson

Deschisă

SectorSănătate

156.81 -5.3

Rezumat

Modificarea prețului

24h

Curent

Minim

156.56

Maxim

166.59

Indicatori cheie

By Trading Economics

Venit

3.4B

Vânzări

20M

23B

P/E

Medie Sector

28.153

73.239

EPS

2.04

Randament dividend

3.03

Marjă de profit

15.235

Angajați

138,100

EBITDA

652M

5.9B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+2.23% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.03%

3.06%

Următoarele câștiguri

15 apr. 2025

Următoarea dată ex-dividende

19 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

26B

394B

Deschiderea anterioară

162.11

Închiderea anterioară

156.81

Sentimentul știrilor

By Acuity

46%

54%

152 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Johnson and Johnson Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mar. 2025, 15:16 UTC

Principalele dinamici ale pieței

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 mar. 2025, 13:59 UTC

Principalele dinamici ale pieței

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

21 mar. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 mar. 2025, 13:35 UTC

Câștiguri
Acțiuni populare

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14 mar. 2025, 09:30 UTC

Top știri

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7 mar. 2025, 01:00 UTC

Top știri

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18 feb. 2025, 22:22 UTC

Top știri

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14 feb. 2025, 13:00 UTC

Top știri

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24 ian. 2025, 07:00 UTC

Top știri

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22 ian. 2025, 21:39 UTC

Câștiguri

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 ian. 2025, 19:41 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 ian. 2025, 17:38 UTC

Market Talk
Câștiguri

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22 ian. 2025, 16:48 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 ian. 2025, 14:51 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22 ian. 2025, 14:09 UTC

Top știri
Câștiguri

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 ian. 2025, 13:04 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22 ian. 2025, 12:47 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

22 ian. 2025, 12:34 UTC

Câștiguri

Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light -- IBD

22 ian. 2025, 12:15 UTC

Market Talk

J&J's 2025 Sales View Misses Wall Street Estimates -- Market Talk

22 ian. 2025, 11:57 UTC

Market Talk
Câștiguri

J&J 4Q Sales Rise on Demand for Cancer Drugs, Medical Devices -- Market Talk

22 ian. 2025, 11:30 UTC

Câștiguri

J&J's Earnings Beat Estimates But Guidance Is Mixed -- MarketWatch

22 ian. 2025, 11:23 UTC

Top știri
Câștiguri

J&J Reports Strong Revenue and Profit But Faces Challenges in 2025 -- WSJ

22 ian. 2025, 11:22 UTC

Top știri
Câștiguri

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 ian. 2025, 11:20 UTC

Câștiguri

Johnson & Johnson: Innovative Medicine 4Q Results Driven by In-Market Portfolio and Continued Uptake From Recently Launched Products, With 10 Brands Growing Double Digits >JNJ

22 ian. 2025, 11:20 UTC

Câștiguri

Johnson & Johnson 4Q Worldwide MedTech Sales $8.19B >JNJ

22 ian. 2025, 11:20 UTC

Câștiguri

Johnson & Johnson 4Q U.S. Sales $13.20B >JNJ

22 ian. 2025, 11:20 UTC

Câștiguri

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 7.6% in 4Q >JNJ

22 ian. 2025, 11:20 UTC

Câștiguri

Johnson & Johnson Sees 2025 Operational Sales of $90.9B-$91.7B >JNJ

22 ian. 2025, 11:20 UTC

Câștiguri

Johnson & Johnson Sees 2025 Adjusted Operational EPS $10.75-$10.95 >JNJ

22 ian. 2025, 11:20 UTC

Câștiguri

Johnson & Johnson Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

Comparație

Modificare preț

Johnson and Johnson Așteptări

Obiectiv de preț

By TipRanks

2.23% sus

Prognoză pe 12 luni

Medie 167.36 USD  2.23%

Maxim 185 USD

Minim 152 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruJohnson and Johnson - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

13 ratings

5

Cumpărare

8

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

162.81 / 164.25Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

152 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.